Implementation of hormonal contraceptive furnishing in San Francisco community pharmacies.
COVID-19
/ epidemiology
Community Pharmacy Services
/ organization & administration
Contraceptives, Oral, Hormonal
/ supply & distribution
Cross-Sectional Studies
Drug Prescriptions
/ statistics & numerical data
Female
Humans
Pharmacists
/ standards
Professional Role
SARS-CoV-2
San Francisco
/ epidemiology
Journal
Journal of the American Pharmacists Association : JAPhA
ISSN: 1544-3450
Titre abrégé: J Am Pharm Assoc (2003)
Pays: United States
ID NLM: 101176252
Informations de publication
Date de publication:
Historique:
received:
18
05
2020
revised:
09
07
2020
accepted:
18
07
2020
pubmed:
18
8
2020
medline:
15
12
2020
entrez:
18
8
2020
Statut:
ppublish
Résumé
In 2013, California passed Senate Bill 493, which allowed pharmacists to furnish hormonal contraceptives without a physician's prescription. Despite this expanded scope of practice, only 11% of the pharmacies reported furnishing hormonal contraception over the following 6 years. Our study objectives were to determine the extent of hormonal contraceptive furnishing and identify the factors that led to successful implementation in San Francisco community pharmacies. Backspace we conducted a cross-sectional survey to identify community pharmacies furnishing hormonal contraception in San Francisco. Interviews were coded inductively to identify consistent themes. Semistructured interviews with pharmacists at the locations that furnished contraception identified the factors that had led to successful implementation in local community pharmacies, as well as assessing changes in practice during the coronavirus disease (COVID-19) pandemic. San Francisco had 113 operational community pharmacies in April 2020. Of these, 21 locations reported that they furnished hormonal contraception (19%), and we interviewed pharmacists at 12 of those locations. We identified 3 key factors that drove implementation at the pharmacy level: administrative support, advertising, and pharmacist engagement. Additional drivers of implementation involved the nature of the community. The respondents also reported on barriers that continued to slow adoption, including consultation fees, time constraints, and patient privacy. Changes in demand for services owing to COVID-19 risks were inconsistent. Our findings suggest strategies that community pharmacies can use to expand their scope of practice and improve quality and continuity of care for patients.
Sections du résumé
BACKGROUND
In 2013, California passed Senate Bill 493, which allowed pharmacists to furnish hormonal contraceptives without a physician's prescription. Despite this expanded scope of practice, only 11% of the pharmacies reported furnishing hormonal contraception over the following 6 years.
OBJECTIVES
Our study objectives were to determine the extent of hormonal contraceptive furnishing and identify the factors that led to successful implementation in San Francisco community pharmacies.
METHODS
Backspace we conducted a cross-sectional survey to identify community pharmacies furnishing hormonal contraception in San Francisco. Interviews were coded inductively to identify consistent themes. Semistructured interviews with pharmacists at the locations that furnished contraception identified the factors that had led to successful implementation in local community pharmacies, as well as assessing changes in practice during the coronavirus disease (COVID-19) pandemic.
RESULTS
San Francisco had 113 operational community pharmacies in April 2020. Of these, 21 locations reported that they furnished hormonal contraception (19%), and we interviewed pharmacists at 12 of those locations. We identified 3 key factors that drove implementation at the pharmacy level: administrative support, advertising, and pharmacist engagement. Additional drivers of implementation involved the nature of the community. The respondents also reported on barriers that continued to slow adoption, including consultation fees, time constraints, and patient privacy. Changes in demand for services owing to COVID-19 risks were inconsistent.
CONCLUSION
Our findings suggest strategies that community pharmacies can use to expand their scope of practice and improve quality and continuity of care for patients.
Identifiants
pubmed: 32800456
pii: S1544-3191(20)30344-7
doi: 10.1016/j.japh.2020.07.019
pmc: PMC7423572
mid: NIHMS1615895
pii:
doi:
Substances chimiques
Contraceptives, Oral, Hormonal
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
963-968.e2Subventions
Organisme : NIDA NIH HHS
ID : R21 DA046051
Pays : United States
Informations de copyright
Copyright © 2020 American Pharmacists Association®. Published by Elsevier Inc. All rights reserved.
Références
Obstet Gynecol. 2019 Jun;133(6):1238-1246
pubmed: 31135740
Pharmacy (Basel). 2019 Jul 18;7(3):
pubmed: 31323818
J Urban Health. 2010 Dec;87(6):931-41
pubmed: 20967505
J Am Pharm Assoc (2003). 2008 Mar-Apr;48(2):212-226
pubmed: 18359734
Best Pract Res Clin Obstet Gynaecol. 2009 Apr;23(2):177-85
pubmed: 19144571
Contraception. 2019 Apr;99(4):239-243
pubmed: 30562478
JAMA. 2017 Dec 12;318(22):2253-2254
pubmed: 29234797
Contraception. 2019 Dec;100(6):464-467
pubmed: 31493380